Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central nervous program, conolidine modulates alternate molecular targets. A Science Developments analyze identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://adamd319yzb0.spintheblog.com/profile